Dana Investment Advisors Inc. Sells 648 Shares of CONMED Co. (NYSE:CNMD)

Dana Investment Advisors Inc. decreased its holdings in shares of CONMED Co. (NYSE:CNMD) by 12.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,657 shares of the company’s stock after selling 648 shares during the period. Dana Investment Advisors Inc.’s holdings in CONMED were worth $640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Champlain Investment Partners LLC grew its position in shares of CONMED by 0.8% during the 1st quarter. Champlain Investment Partners LLC now owns 1,704,939 shares of the company’s stock valued at $222,648,000 after acquiring an additional 12,925 shares during the period. Earnest Partners LLC grew its position in shares of CONMED by 3.9% during the 1st quarter. Earnest Partners LLC now owns 1,636,672 shares of the company’s stock valued at $213,733,000 after acquiring an additional 61,336 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of CONMED by 77.5% during the 1st quarter. Ameriprise Financial Inc. now owns 755,437 shares of the company’s stock valued at $98,654,000 after buying an additional 329,938 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of CONMED by 118.5% during the 1st quarter. Loomis Sayles & Co. L P now owns 645,739 shares of the company’s stock valued at $84,327,000 after buying an additional 350,239 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of CONMED by 8.0% during the 1st quarter. Geode Capital Management LLC now owns 441,841 shares of the company’s stock valued at $57,700,000 after buying an additional 32,608 shares in the last quarter.

In other CONMED news, EVP John Jed Kennedy sold 5,438 shares of the business’s stock in a transaction on Friday, August 27th. The shares were sold at an average price of $134.77, for a total value of $732,879.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Todd W. Garner sold 1,350 shares of the business’s stock in a transaction dated Friday, August 13th. The stock was sold at an average price of $122.76, for a total transaction of $165,726.00. Following the completion of the sale, the chief financial officer now owns 1,322 shares in the company, valued at $162,288.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,028 shares of company stock worth $1,469,945. Corporate insiders own 1.10% of the company’s stock.

CNMD opened at $125.03 on Wednesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.17 and a current ratio of 2.23. CONMED Co. has a fifty-two week low of $69.60 and a fifty-two week high of $146.95. The firm’s fifty day moving average is $130.51 and its 200 day moving average is $132.67. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of 71.04, a price-to-earnings-growth ratio of 3.88 and a beta of 1.58.

CONMED (NYSE:CNMD) last announced its quarterly earnings results on Wednesday, July 28th. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.62 by $0.09. The business had revenue of $255.16 million for the quarter, compared to analysts’ expectations of $247.87 million. CONMED had a net margin of 5.53% and a return on equity of 12.89%. On average, equities research analysts predict that CONMED Co. will post 3.19 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 5th. Shareholders of record on Wednesday, September 15th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Tuesday, September 14th. CONMED’s payout ratio is currently 36.70%.

A number of research analysts recently weighed in on CNMD shares. UBS Group started coverage on shares of CONMED in a research note on Thursday, July 15th. They set a “buy” rating and a $160.00 target price on the stock. Barclays started coverage on shares of CONMED in a research note on Monday, May 24th. They set an “overweight” rating and a $175.00 target price on the stock.

About CONMED

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific.

Featured Story: Most Volatile Stocks

Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Co. (NYSE:CNMD).

Institutional Ownership by Quarter for CONMED (NYSE:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.